Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). GeneThera's share price for the quarter that ended in Sep. 2022 was $0.0156. GeneThera's Shares Outstanding (EOP) for the quarter that ended in Sep. 2022 was 35.33 Mil. Therefore, GeneThera's market cap for the quarter that ended in Sep. 2022 was $0.55 Mil.
GeneThera's quarterly market cap
declined
from Mar. 2022 ($1.30 Mil) to Jun. 2022 ($0.76 Mil) and
declined
from Jun. 2022 ($0.76 Mil) to Sep. 2022 ($0.55 Mil).
GeneThera's annual market cap
declined
from Dec. 2019 ($0.36 Mil) to Dec. 2020 ($0.34 Mil) but then
increased
from Dec. 2020 ($0.34 Mil) to Dec. 2021 ($1.10 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GeneThera's Enterprise Value for Today is $1.05 Mil.
GeneThera Market Cap Historical Data
The historical data trend for GeneThera's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, GeneThera's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneThera's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GeneThera's Market Cap distribution charts can be found below:
* The bar in red indicates where GeneThera's Market Cap falls into.
GeneThera Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
GeneThera's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneThera (OTCPK:GTHR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
GeneThera Market Cap Related Terms
Thank you for viewing the detailed overview of GeneThera's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTHR has been successfully added to your 